Loading patent…
OwnerAnja Katrin Bosserhoff, Burkhard König +2inventors
InventorsAnja Katrin Bosserhoff, Burkhard König, Alexander Riechers, Jennifer Schmidt
Estimating the term…
The present invention relates to peptides and antibodies which bind to melanoma inhibitory activity protein and the uses of such peptides and antibodies. The invention also relates to nucleic acids coding for such peptides or antibodies. The invention also relates to pharmaceutical compositions comprising such peptides or antibodies or such nucleic acids. The present invention also relates to small molecule compounds which bind to melanoma inhibitory activity protein and to uses of such small molecule compounds. Moreover, the present invention also relates to a method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein. The invention is based on the identification of the relevant sites of interaction of the MIA protein with the inhibitory peptides/antibodies. Considering the amino acid sequence of this protein deprived from the signalling peptide, the residues involved in the interaction are selected from: A7, K53, G54, R55, R57, L58, F59, V64, Y69, R85, D87, K91, and more preferably C17, S18, Y47, G61, G66, D67, L76, W102, D103, C106.
1-22. (canceled)
A peptide or antibody that binds to melanoma inhibitory activity (MIA) protein and prevents dimerization and/or aggregation thereof, which peptide is not SEQ ID NO:46 or 47, wherein binding of said peptide to MIA protein occurs at a surface of said MIA protein formed by at least three amino acid residues of said MIA protein selected from cysteine 17, serine 18, tyrosine 47, glycine 61, glycine 66, aspartate 67, leucine 76, tryptophan 102, aspartate 103, cysteine 106, valine 64, tyrosine 69, aspartate 87, lysine 91, glycine 54, leucine 58, phenylalanine 59, alanine 7, lysine 53, arginine 55, arginine 57, arginine 85, and lysine 94, preferably cysteine 17, serine 18, tyrosine 47, glycine 61, glycine 66, aspartate 67, leucine 76, tryptophan 102, aspartate 103, cysteine 106, alanine 7, lysine 53, arginine 55, arginine 57, arginine 85 and lysine 94, more preferably cysteine 17, serine 18, tyrosine 47, glycine 61, glycine 66, aspartate 67, leucine 76, tryptophan 102, aspartate 103 and cysteine 106.
A method of preventing dimerization and/or aggregation of melanoma inhibitory activity (MIA) protein, said method comprising:
The antibody, according to claim 43, having an amino acid sequence selected from SEQ ID NOs:1-9.
The method, according to claim 37, wherein said peptide has an amino acid sequence selected from SEQ ID NOs:1-9.
Dependencies are inferred from the claim text.